Exome Asset Management LLC Takes Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)

Exome Asset Management LLC bought a new position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) in the third quarter, Holdings Channel reports. The institutional investor bought 116,757 shares of the company’s stock, valued at approximately $817,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Barclays PLC boosted its stake in shares of Acrivon Therapeutics by 51.2% in the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after purchasing an additional 11,273 shares in the last quarter. State Street Corp lifted its stake in Acrivon Therapeutics by 26.4% in the third quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after purchasing an additional 47,233 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Acrivon Therapeutics by 78.2% in the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock worth $31,093,000 after purchasing an additional 2,353,000 shares during the last quarter. Marshall Wace LLP boosted its position in Acrivon Therapeutics by 58.8% during the second quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock valued at $5,503,000 after buying an additional 351,397 shares during the period. Finally, Sands Capital Ventures LLC grew its stake in shares of Acrivon Therapeutics by 28.4% during the second quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock valued at $12,311,000 after buying an additional 470,000 shares during the last quarter. 71.62% of the stock is currently owned by institutional investors.

Acrivon Therapeutics Price Performance

NASDAQ:ACRV opened at $7.06 on Friday. The firm has a market capitalization of $219.85 million, a P/E ratio of -2.61 and a beta of 0.55. The company’s 50-day simple moving average is $7.48 and its 200 day simple moving average is $7.57. Acrivon Therapeutics, Inc. has a one year low of $3.19 and a one year high of $11.90.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Piper Sandler Companies reissued a “buy” rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a research note on Friday, September 6th. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Acrivon Therapeutics in a report on Thursday, November 14th. LADENBURG THALM/SH SH raised shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Monday, September 16th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 target price on shares of Acrivon Therapeutics in a research report on Monday, September 16th. Finally, BMO Capital Markets cut their target price on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Acrivon Therapeutics currently has an average rating of “Buy” and an average price target of $23.67.

Acrivon Therapeutics Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.